BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 25942537)

  • 21.
    Buscarlet M; Provost S; Zada YF; Barhdadi A; Bourgoin V; Lépine G; Mollica L; Szuber N; Dubé MP; Busque L
    Blood; 2017 Aug; 130(6):753-762. PubMed ID: 28655780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.
    Abdel-Wahab O; Levine RL
    Blood; 2013 May; 121(18):3563-72. PubMed ID: 23640996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease.
    Sano S; Oshima K; Wang Y; Katanasaka Y; Sano M; Walsh K
    Circ Res; 2018 Jul; 123(3):335-341. PubMed ID: 29728415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.
    Chopra M; Bohlander SK
    Cancer Genet; 2015 May; 208(5):192-205. PubMed ID: 25592767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetics: reversible tags.
    Wright J
    Nature; 2013 Jun; 498(7455):S10-1. PubMed ID: 23803942
    [No Abstract]   [Full Text] [Related]  

  • 28. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models.
    Ono R; Masuya M; Inoue N; Shinmei M; Ishii S; Maegawa Y; Maharjan BD; Katayama N; Nosaka T
    PLoS One; 2021; 16(3):e0248425. PubMed ID: 33705482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL).
    Kn H; Bassal S; Tikellis C; El-Osta A
    Cancer Biol Ther; 2004 Oct; 3(10):989-94. PubMed ID: 15467427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetics of hematopoiesis and hematological malignancies.
    Hu D; Shilatifard A
    Genes Dev; 2016 Sep; 30(18):2021-2041. PubMed ID: 27798847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of epigenetic regulation of leukemia onset and progression.
    Ntziachristos P; Mullenders J; Trimarchi T; Aifantis I
    Adv Immunol; 2013; 117():1-38. PubMed ID: 23611284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations to
    Venugopal K; Feng Y; Shabashvili D; Guryanova OA
    Cancer Res; 2021 Jan; 81(2):254-263. PubMed ID: 33087320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatic alterations and dysregulation of epigenetic modifiers in cancers.
    Aumann S; Abdel-Wahab O
    Biochem Biophys Res Commun; 2014 Dec; 455(1-2):24-34. PubMed ID: 25111821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetics in normal and malignant hematopoiesis: An overview and update 2017.
    Goyama S; Kitamura T
    Cancer Sci; 2017 Apr; 108(4):553-562. PubMed ID: 28100030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women.
    Wiedmeier JE; Kato C; Zhang Z; Lee H; Dunlap J; Nutt E; Rattray R; McKay S; Eide C; Press R; Mori M; Druker B; Dao KH
    Exp Hematol; 2016 Sep; 44(9):857-865.e5. PubMed ID: 27235757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The significance of the epigenetics modifying gene mutations in acute myeloid leukemia].
    Wakita S; Yamaguchi H
    Nihon Rinsho; 2014 Jun; 72(6):1026-32. PubMed ID: 25016799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NSD2 as a Promising Target in Hematological Disorders.
    Azagra A; Cobaleda C
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Involvement of aberrant DNA methylation in hematological malignancies].
    Matsui H
    Rinsho Ketsueki; 2014 Oct; 55(10):1709-14. PubMed ID: 25297731
    [No Abstract]   [Full Text] [Related]  

  • 40. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
    Riedel SS; Haladyna JN; Bezzant M; Stevens B; Pollyea DA; Sinha AU; Armstrong SA; Wei Q; Pollock RM; Daigle SR; Jordan CT; Ernst P; Neff T; Bernt KM
    J Clin Invest; 2016 Apr; 126(4):1438-50. PubMed ID: 26927674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.